Kühne T, Imbach P
Division of Oncology/Haematology, University Children's Hospital, Basel, Switzerland.
Semin Thromb Hemost. 1998;24(6):549-53. doi: 10.1055/s-2007-996054.
Immune thrombocytopenic purpura (ITP) is a bleeding disorder and is traditionally divided in acute and chronic forms based on the duration of the disease. Chronic ITP is characterized by a persistence of thrombocytopenia for more than 6 months. Ten to 20% of children with ITP and almost all adults will develop the chronic condition. Pathophysiology of chronic ITP suggests an autoimmune process and a dysregulated immune response. There are no risk factors to predict the clinical course of ITP. Controlled clinical trials are needed to clarify many diagnostic and therapeutic aspects of chronic ITP, as recently stated by a panel of pediatric and adult hematologists on behalf of The American Society of Hematology (ASH). In this article, we will focus on pathophysiological, diagnostic, and management aspects of chronic childhood ITP.
免疫性血小板减少性紫癜（ITP）是一种出血性疾病，传统上根据病程长短分为急性和慢性两种形式。慢性ITP的特征是血小板减少持续超过6个月。10%至20%的ITP患儿以及几乎所有成年患者会发展为慢性疾病。慢性ITP的病理生理学提示存在自身免疫过程和免疫反应失调。目前尚无预测ITP临床病程的危险因素。正如一组儿科和成人血液学家代表美国血液学会（ASH）最近指出的，需要进行对照临床试验来阐明慢性ITP的许多诊断和治疗方面的问题。在本文中，我们将重点关注儿童慢性ITP的病理生理、诊断和管理方面的问题。
